Last edition
News about "Mike Davis"
US FDA Expands OTC Access to Naloxone Nasal Spray for Opioid Overdose
US FDA expands Over-the-Counter (OTC) access to naloxone nasal spray for opioid overdose, supporting efforts to prevent overdose deaths and strengthen addiction recovery initiatives under the US government’s public health strategy.
Mike Davis | 18/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members